Clinical Trial Disclosure Rule Warns Of Legal Penalties For Failure To Submit
Executive Summary
Final rule for submitting summary results to ClinicalTrials.gov extends to early studies of unapproved products.
You may also be interested in...
NIH Funding Component of 21st Century Cures May Get White House Boost
Vice President’s Cancer Moonshot project could provide final thrust for '21st Century Cures' bill in the lame duck Congressional session after election.
Clinical Trial Reporting Would Expand To Unapproved Drugs Under FDA, NIH Reg
Advocates may press for even more disclosures to better understand economics of clinical research.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.